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Available online 1 July 2007AbstractThe roles of the a2-adrenoceptor (a2-AR) subtypes (a2A-, a2B- and a2C-AR) in uterine contractility have not been investigated. The aims of this
study were to identify these receptors in the non-pregnant and the late-pregnant rat myometrium and to determine their roles in contractions. We
found that the myometrial a2-AR subtypes are involved differently in the control of late-pregnant contractions, while they have no influence on the
contractions of the non-pregnant myometrium.
The myometrial expressions of the a2-AR subtypes were determined by RT-PCR and Western blotting techniques. In vitro contractions were
stimulated with noradrenaline, and its effect was modified with the selective antagonists BRL 44408 (a2A), ARC 239 (a2B/C) and spiroxatrine
(a2C). cAMP production was followed by noradrenaline stimulation in the presence of isobutylmethylxanthine and forskolin, and alterations
induced in it by the antagonists were determined with an Enzyme Immunoassay Kit. The most effective antagonist was tested on labour-induced
uteri in vitro.
All the a2-AR subtypes were identified in both non-pregnant and pregnant uteri. Noradrenaline was not able to contract the non-pregnant tissue
in the presence of propranolol and doxazosin, while its contracting effect in the pregnant uteri was enhanced by BRL 44408, spiroxatrine and the
combination BRL 44408 + spiroxatrine. ARC 239 exerted a strong inhibitory effect on noradrenaline-stimulated contractions. The increasing and
the decreasing effects of the compounds were confirmed by the changes in the intracellular cAMP levels. The effect of ARC 239 on the labour-
induced myometrium was similar to that on the 22-day-pregnant myometrium.
The stimulation of a2-ARs does not evoke contractions in the non-pregnant uterus. The a2A- and a2C-ARs mediate decreases, while the a2B-AR
mediates an increase in the contractions in the 22-day-pregnant myometrium. These differences may offer new targets for drugs against premature
contractions in pregnancy.
# 2007 Published by Elsevier Ltd.
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of uterine contractility. It is well known that stimulation of the
myometrial b2-adrenoceptors (b2-ARs) increases the intracel-
lular cAMP level and causes uterine relaxation (Stiles et al.,
1984), while the a1-AR agonists elicit contractions via increases
in the intracellular inositol phosphate and Ca2+ levels (Michelotti
et al., 2000). The roles of thea2-ARs, however, are not fully clear
from the aspect of myometrial contractility. Earlier studies
proved the presence of a2-ARs in the uterus in several species,* Corresponding author. Tel.: +36 62 545567; fax: +36 62 545567.
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doi:10.1016/j.neuint.2007.06.029e.g. rat, swine and human (Bottari et al., 1985; Kyozuka et al.,
1988; Taneike et al., 1995). Kyozuka et al. (1988) suggested that
there was no connection between the non-pregnant myometrial
a2-ARs and contractility. Non-subtype-selectivea2-AR agonists
were found to increase the contractions of the isolated pregnant
uterus both in swine and in human (Kitazawa et al., 2000; Sia
et al., 2005). Other authors claimed that pregnancy may alter the
signal transduction processes of some ARs, including a2-ARs,
which may modify the response mediated by the ARs (Zhou
et al., 2000).
The identification of the a2-AR subtypes (Bylund et al.,
1994) led to a more complicated background as concerns the
understanding and interpretation of the roles of the a2-ARs in
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a2B-AR and a2C-AR) have been identified in the human
myometrium, while only a2A-ARs and a2B-ARs have been
found in the rat uterus (Bouet-Alard et al., 1997). To date there
has been no investigation of the roles of the different a2-AR
subtypes in the control of uterine smooth muscle contractions.
The existence of a2-AR subtype-selective compounds offers a
good possibility for determination of the functions of the given
subtypes.
The aims of this study were to identify the a2-AR subtypes
in the non-pregnant and the late-pregnant rat myometrium and
to determine their roles in contractions.
1. Experimental procedures
1.1. Housing and handling of the animals
The animals were treated in accordance with the European Communities
Council Directives (86/609/ECC) and the Hungarian Act for the Protection of
Animals in Research (XXVIII.tv.32.§). All experiments involving animal
subjects were carried out with the approval of the Hungarian Ethical Committee
for Animal Research (registration number: IV/1813-1/2002). Sprague–Dawley
rats (Charles-River Laboratories, Hungary) were kept at 22  3 8C; the relative
humidity was 30–70% and the light/dark cycle was 12/12 h. They were
maintained on a standard rodent pellet diet (Charles-River Laboratories,
Hungary) with tap water available ad libitum. The animals were sacrificed
by CO2 inhalation.
1.2. Mating of the animals
Mature female (180–200 g) and male (240–260 g) rats were mated in a
special mating cage. A metal door, which was movable by a small electric
engine, separated the rooms for the male and female animals. A timer controlled
the function of the engine. Since rats are usually active at night, the separating
door was opened before dawn. Within 4–5 h after the possibility of mating,
vaginal smears were taken from the female rats, and a sperm search was
performed under a microscope at a magnification of 1200 times. If the search
proved positive, or if smear taking was impossible because of an existing




Uterine tissues from non-pregnant and 22-day-pregnant animals were
rapidly removed, and the embryonic tissues were separated. The uteri were
frozen in liquid nitrogen and then stored at 70 8C until total RNA extraction.
1.3.2. Total RNA preparation
Total cellular RNA was isolated by extraction with acid guanidinium
thiocyanate–phenol–chloroform by the procedure of Chomczynski and Sacchi
(1987). After precipitation with isopropanol, the RNA was washed three times
with ice-cold 75% ethanol and then dried. The pellet was resuspended in 100 ml
DNase- and RNase-free distilled water. The RNA concentrations of the samples
were determined from their absorbances at 260 nm.
1.3.3. RT-PCR
The RNA (0.5 mg) was denatured at 70 8C for 5 min in a reaction mixture
containing 20 mM oligo(dT) (Hybaid Corp., UK), 20 U RNase inhibitor
(Hybaid Corp., UK), 200 mM dNTP (Sigma–Aldrich, USA) in 50 mM Tris–
HCl, pH 8.3, 75 mM KCl and 5 mM MgCl2 in a final reaction volume of 20 ml.
After the mixture had been cooled to 4 8C, 20 U MMLV reverse transcriptase
(GIBCO, UK) and RNase H Minus (Promega, UK) were added, and the mixture
was incubated at 37 8C for 60 min.The PCR was carried out with 5 ml cDNA, 25 ml ReadyMix REDTaq PCR
reaction mix (Sigma–Aldrich, USA), 2 ml 50 pM sense and antisense primers of
the a2-AR subtypes (GeneBank codes: NM_012739 for a2A-AR; AF366899 for
a2B-AR; NM_138506 for a2C-AR) and 16 ml DNase- and RNase-free distilled
water. The coupling temperatures and numbers of cycles for the different a2-AR
subtypes were as follows: 57 8C, 32 cycles for a2A-AR; 56 8C, 32 cycles for
a2B-AR; 59 8C, 36 cycles for a2C-AR.
Glyceraldehyde-3-phosphate dehydrogenase primers were used as internal
controls in all samples (Tso et al., 1985). The PCR was performed with a PCR
Sprint thermal cycler (Hybaid Corp., UK). After the initial denaturation at
95 8C for 5 min, the reactions were taken through the previously determined
number of cycles for each a2-AR subtype: 60 s at 95 8C, 60 s at the appropriate
coupling temperature and 60 s at 72 8C, followed by lowering of the tem-
perature to 4 8C. This PCR protocol furnished optimized conditions and linear
phase amplification for each of the primer sets employed. The optimum
number of cycles for each set of primers was determined by performing
kinetic analyses.
The RT-PCR products were separated on 2% agarose gels, stained with
ethidium bromide and photographed under a UV transilluminator. Semiquan-
titative analysis was performed by densitometric scanning of the gel with Kodak
EDAS290 (Csertex Ltd., Hungary). For statistical evaluations, data were
analysed by the use of ANOVA, followed by the Neuman–Keuls test.
1.4. Western blotting studies
Twenty micrograms of protein per well was subjected to electrophoresis on
10% sodium dodecylsulfate polyacrylamide gels in Series Standard Dual
Cooled Units (BioRad, Hungary). Proteins were transferred from gels to
nitrocellulose membranes (Scheicher and Schuell, Germany), using a semidry
blotting technique (BioRad, Hungary). The membranes were blocked with 5%
non-fat dry milk in Tris saline buffer (50 mM Tris, pH 7.4, 200 mM NaCl)
containing 0.1% Tween, overnight at 4 8C. After washing, the blots were
incubated for 1 h at room temperature on a shaker with a2A-, a2B-, and
a2C-AR and b-actin polyclonal antibody (Santa Cruz Biotechnology, Califor-
nia, USA, 1:200) in the blocking buffer. Immunoreactive bands were visualized
with the WesternBreeze Chromogenic Western blot immunedetection kit
(Invitrogen, Hungary) and quantified. For statistical evaluations, data were
analysed via the ANOVA, followed by the Neuman–Keuls test.
1.5. Isolated organ bath studies
Uteri were removed from non-pregnant (180–200 g), 22-day-pregnant
(270–350 g), and labour-induced 20-day-pregnant rats (240–300 g). Muscle
rings 5 mm long were sliced from the uterine horns and mounted in an organ
bath (8 parallels) containing 10 ml de Jongh solution (in mM: 137 NaCl, 3
KCl, 1 CaCl2, 1 MgCl2, 12 NaHCO3, 4 NaH2PO4, 6 glucose, pH 7.4). The
organ bath was maintained at 37 8C, and carbogen (95% O2 + 5% CO2) was
bubbled through it. After mounting, the rings were equilibrated for about 1 h
before experiments were undertaken, with a solution change every 15 min.
The initial tension was set to about 1.25 g, which was relaxed to about 0.5 g
at the end of equilibration. The tension of the myometrial rings was measured
and recorded with a gauge transducer and an S.P.E.L. Advanced ISOSYS
Data Acquisition System (Experimetria Ltd., Hungary), respectively. Con-
tractions were elicited with noradrenaline (1  108 to 3  105 M) and
cumulative concentration–response curves were constructed in each experi-
ment in the presence of propranolol (105 M) and doxazosin (107 M) in
order to avoid b- and a1-adrenergic actions. a2-AR antagonists (each
107 M) were left to incubate for 20 min before the administration of
contracting agents. Following the addition of each concentration of nora-
drenaline, recording was performed for 300 s. Concentration–response
curves were fitted and areas under curves (AUCs) were evaluated and
analysed statistically with the Prism 4.0 (GraphPad Software, USA) com-
puter program. From the AUC values, Emax and EC50 values were calculated
(Emax: the maximum contracting effect of noradrenaline alone or in the
presence of an a2-AR antagonist; EC50: the concentration of noradrenaline
alone or in the presence of an a2-AR antagonist which elicits half of the
maximum contracting effect of noradrenaline). For statistical evaluations,
data were analysed by two-tailed unpaired t-test.
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Uterine cAMP accumulation was measured with a commercial cAMP
Enzyme Immunoassay Kit (Sigma–Aldrich, Hungary). Briefly, the kit uses a
polyclonal antibody to cAMP to bind, in a competitive manner, the cAMP in the
sample or an alkaline phosphatase molecule that has cAMP covalently attached
to it. On a secondary antibody-coated microwell plate, the cAMP–antibody and
the alkaline phosphatase–antibody complexes are conjugated. Following the
addition of p-nitrophenyl phosphate, a substrate of alkaline phosphatase, the p-
nitrophenol generated can be determined via its yellow colour at 405 nm. The
more intense the colour, the lower the amount of intracellular cAMP.
Uterine tissue samples from non-pregnant and 22-day-pregnant rats were
incubated in an organ bath (10 ml) containing de Jongh buffer (37 8C, perfused
with carbogen). Isobutylmethylxanthine (103 M), doxazosin (107 M), pro-
pranolol (105 M) and the investigated subtype-selective a2-AR antagonists
(each 107 M) were incubated with the tissues for 20 min, and noradrenaline
(3  106 M) was then added for 10 min. At the end of the noradrenaline
incubation period, forskolin (105 M) was added for another 10 min, as
described by Roberts et al. (1998). After this, the samples were immediately
frozen and stored in liquid nitrogen until cAMP extraction. The tissue samples
were next ground under liquid nitrogen, weighed, homogenized in 10 volumes
of ice-cold 5% trichloroacetic acid and centrifuged at 600  g for 10 min.
The supernatant was extracted with three volumes of water-saturated diethyl
ether. After drying, the extracts were stored at 70 8C until the cAMP assay.
The cAMP content was expressed in pmol (mg tissue)1. For statistical
evaluations, data were analysed with ANOVA, followed by the Neuman–
Keuls test.
1.7. Induction of premature labour in pregnant rat
The experimental premature labour procedure was carried out according to
the model of Rechberger et al. (1996). Briefly, 19-day-pregnant rats were treatedFig. 1. The expressions of the mRNAs of the a2-adrenoceptor (a2-AR) subtypes in
The results were expressed as the ratio of the optical densities of the AR subtype and
subtype mRNAs were found in both the non-pregnant and the pregnant uteri. In the no
significance by ANOVA followed by the Neuman–Keuls test: a2A-AR vs.a2B-AR, p <
day-pregnant uteri, (c) an a2B-AR mRNA predominance was detected (levels of sign
p < 0.05;a2B-AR vs.a2C-AR, p < 0.001;a2A-AR vs.a2C-AR, p < 0.01). (b and d) G
PCR) products from the total RNA from non-pregnant (b) and 22-day-pregnant (d) u
and 425 base pair (bp) RT-PCR products correspond to the mRNA of GAPDH, awith s.c. antiprogesterone (mifepristone) at 3 mg/animal at 9.00 a.m. At
4.00 p.m., prostaglandin E2 (0.5 mg/animal) was administered intravaginally.
Our preliminary results had revealed that, after this treatment, the pregnant
animals delivered between 9.00 and 10.00 a.m. on day 20 of pregnancy.
Accordingly, the animals were sacrificed and uterine tissues were removed
at 9.00 a.m., ensuring that the pregnant myometrium was very close to, but not
after delivery.
1.8. Materials
Noradrenaline, isobutylmethylxanthine, forskolin, mifepristone, spiroxa-
trine and prostaglandin E2 were purchased from Sigma–Aldrich, Hungary; BRL
44408 (2-[2H-(1-methyl-1,3-dihydroisoindole)methyl]-4,5-dihydroimidazole)
and ARC 239 (2-[2,4-(O-methoxyphenyl)-piperazin]-1-yl dihydrochloride
were purchased from Tocris, UK. Doxazosin was donated by Pfizer Hungary
Ltd., Hungary.
2. Results
2.1. RT-PCR and Western blotting studies
RT-PCR studies revealed the mRNAs of all three a2-AR
subtypes in both the non-pregnant and the 22-day-pregnant rat
uteri. In the non-pregnant animals, there was a slight
predominance of a2A-AR mRNA (Fig. 1a and b), and in the
pregnant myometrium a strong a2B-AR mRNA predominance
(Fig. 1c and d). The Western blotting analysis gave a result for
the non-pregnant uteri similar to that from the RT-PCR studies
(Fig. 2a and b). In the pregnant myometrium, the predominantnon-pregnant (a and b) and 22-day-pregnant (c and d) rat uteri (n = 5). (a and c)
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNAs (S.E.M.). All
n-pregnant uteri, (a) a slight a2A-AR mRNA predominance was found (levels of
0.01;a2A-AR vs.a2C-AR, p < 0.01;a2B-AR vs.a2C-AR, p > 0.05). In the 22-
ificance by ANOVA followed by the Neuman–Keuls test: a2B-AR vs. a2A-AR,
APDH anda2-AR subtype reverse transcription-polymerase chain reaction (RT-
teri. Each band contains RNA from the uterus of one animal. The 600, 312, 456
2A-, a2B- and a2C-AR, respectively.
Fig. 2. The expressions of the a2-adrenoceptor (a2-AR) subtype protein in non-pregnant (a and b) and 22-day-pregnant (c and d) rat uteri (n = 5). (a and c) The results
were expressed as the ratio of the optical densities of the receptor subtypes and b-actin proteins (S.E.M.). All subtype proteins were found in both the non-pregnant
and the pregnant uteri. In the non-pregnant uteri, (a) no differences were observed between the expressions of the proteins of the a2-AR subtypes. In the 22-day-
pregnant uteri, (c) an a2B-AR protein predominance was detected (levels of significance by ANOVA followed by the Neuman–Keuls test: a2B-AR vs. a2A-AR,
p < 0.001; a2B-AR vs. a2C-AR, p < 0.01; a2A-AR vs. a2C-AR, p < 0.001). (b and d) The a2-AR subtype and b-actin Western blotting products from non-pregnant
(b) and 22-day-pregnant (d) rat uteri. Each pair of bands (a2-AR subtypes and b-actin) contains proteins from the uterus of one animal. Samples were subjected to gel
electrophoresis on 10% polyacrylamide gel. The antibody binding was detected with an enhanced chemiluminescence detection system.
Fig. 3. Effect of the subtype-selective a2A-adrenoceptor antagonist BRL 44408
on the noradrenaline-evoked contractions (control) in the 22-day-pregnant rat
myometrium in an isolated organ bath (n = 8). The studies were carried out in
the presence of the b-adrenoceptor antagonist propranolol (105 M) and the a1-
adrenoceptor antagonist doxazosin (107 M). The change in contraction was
calculated via the area under the curves and expressed in %  S.E.M. The
statistical analyses were carried out with the two-tailed unpaired t-test.
*p < 0.05. BRL 44408 at 107 M increased the maximum contracting effect
of noradrenaline. For EC50 and Emax values, see Table 1.
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density of the a2A-AR protein was significantly lower than that
of the a2C-AR (Fig. 2c and d).
2.2. Isolated organ studies with non-pregnant and 22-day-
pregnant myometria
Noradrenaline in the concentration range 108 to 104.5 M
did not exert a contractile effect on the non-pregnant uterine
rings, whereas vivid contractions were elicited by 25 mM KCl
(data not shown). In the 22-day-pregnant myometrium,
noradrenaline concentration-dependently increased the con-
tractions, and these were slightly increased by the a2A-AR
antagonist BRL 44408 (Fig. 3). The a2B/C-AR antagonist ARC
239 significantly decreased the maximum effect of noradrena-
line (Fig. 4), while the a2C-AR antagonist spiroxatrine
enhanced the noradrenaline-induced contractions (Fig. 5).
The combination BRL 44408 + spiroxatrine also caused an
increase in the maximum myometrium-contracting effect of
noradrenaline (Fig. 6). The EC50 and Emax values of the curves
are listed in Table 1.
2.3. cAMP studies
In the non-pregnant uterine tissue, BRL 44408, ARC 239,
spiroxatrine, and the combination BRL 44408 + spiroxatrine
did not influence the amount of cAMP produced in the
presence of 3  106 M noradrenaline (data not shown). In the
pregnant uteri, ARC 239 was able to increase the cAMP levelproduced by noradrenaline, while BRL 44408, spiroxatrine
and the combination BRL 44408 + spiroxatrine caused
significant decreases in the amount of myometrial cAMP
(Fig. 7).
Fig. 4. Effect of the subtype-selective a2B/C-adrenoceptor antagonist ARC 239
on the noradrenaline-evoked contractions (control) in the 22-day-pregnant rat
myometrium in an isolated organ bath (n = 8). The studies were carried out in
the presence of the b-adrenoceptor antagonist propranolol (105 M) and the a1-
adrenoceptor antagonist doxazosin (107 M). The change in contraction was
calculated via the area under the curves and expressed in %  S.E.M. The
statistical analyses were carried out with the two-tailed unpaired t-test.
*p < 0.05; **p < 0.01. ARC 239 at 107 M decreased the maximum contract-
ing effect of noradrenaline. For EC50 and Emax values, see Table 1.
Fig. 6. Effects of the subtype-selective a2A-adrenoceptor antagonist BRL
44408 and a2C-adrenoceptor antagonist spiroxatrine on the noradrenaline-
evoked contractions (control) in the 22-day-pregnant rat myometrium in an
isolated organ bath (n = 8). The studies were carried out in the presence of theb-
adrenoceptor antagonist propranolol (105 M) and the a1-adrenoceptor antago-
nist doxazosin (107 M). The change in contraction was calculated via the area
under the curves and expressed in %  S.E.M. The statistical analyses were
carried out with the two-tailed unpaired t-test. *p < 0.05; **p < 0.01. BRL
44408 and spiroxatrine at 107 M increased the maximum contracting effect of
noradrenaline. For EC50 and Emax values, see Table 1.
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hormonally induced preterm birth
Noradrenaline (108.5 to 105 M) enhanced the contrac-
tions of labour-induced uterine rings, although its effect wasFig. 5. Effect of the subtype-selective a2C-adrenoceptor antagonist spiroxatrine
on the noradrenaline-evoked contractions (control) in the 22-day-pregnant rat
myometrium in an isolated organ bath (n = 8). The studies were carried out in
the presence of the b-adrenoceptor antagonist propranolol (105 M) and the a1-
adrenoceptor antagonist doxazosin (107 M). The change in contraction was
calculated via the area under the curves and expressed in %  S.E.M. The
statistical analyses were carried out with the two-tailed unpaired t-test.
*p < 0.05. Spiroxatrine at 107 M increased the maximum contracting effect
of noradrenaline. For EC50 and Emax values, see Table 1.less than that in the 22-day-pregnant animals. ARC 239
blocked the noradrenaline-evoked contractions (Fig. 8).
The EC50 and Emax values of the curves are presented in
Table 2.Fig. 7. Effects of the subtype-selective a2-adrenoceptor antagonists on the
myometrial cAMP level (pmol/mg tissue  S.E.M.) stimulated by noradrena-
line in the presence of isobutylmethylxanthine and forskolin (control) in the 22-
day-pregnant rat (n = 6). The studies were carried out in the presence of the b-
adrenoceptor antagonist propranolol (105 M) and the a1-adrenoceptor antago-
nist doxazosin (107 M). cAMP production was increased by IBMX (103 M)
and forskolin (105 M). The statistical analyses were carried out with ANOVA
followed by the Neuman–Keuls test. *p < 0.05; **p < 0.01. The antagonist
concentrations were 107 M in each case. The myometrial cAMP produced by
3  106 M noradrenaline was increased by ARC 239 (ARC), while BRL
44408 (BRL), spiroxatrine and the combination BRL 44408 + spiroxatrine
(BRL + spir.) decreased its level.
Table 1
Changes in the 22-day pregnant uterus-contracting effect of noradrenaline (EC50 and Emax values) in the presence of subtype-selective a2-AR antagonists (10
7 M)
Stimulated a2-ARs EC50  S.E.M. (M) Emax  S.E.M. (%)
Noradrenaline (control) a2A-, a2B- and a2C-ARs 2.6  106  0.8  106 295.1  30.3
Noradrenaline + BRL 44408 a2B- and a2C-ARs 1.8  106  0.9  106 377.0  51.8
Noradrenaline + ARC 239 a2A-ARs 1.2  106  1.3  106 154.4  34.5
Noradrenaline + spiroxatrine a2A- and a2B-ARs 1.8  106  1.1  106 408.0  41.5
Noradrenaline + BRL 44408 + spiroxatrine a2B-ARs 2.7  106  1.0  106 446.8  34.8
EC50: the concentration of noradrenaline alone or in the presence of an a2-AR antagonist which elicits half the maximum contracting effect of noradrenaline. Emax:
maximum contracting effect of noradrenaline alone or in the presence of the a2-AR antagonists.
Table 2
Changes in the labour-induced uterus-contracting effect of noradrenaline (EC50 and Emax values) in the presence of a2BC-AR antagonist ARC 239 (10
7 M)
Stimulated a2-ARs EC50  S.E.M. (M) Emax  S.E.M. (%)
Noradrenaline (control) a2A-, a2B- and a2C-ARs 3.4  107  1.6  107 100.3  100.4
Noradrenaline + ARC 239 a2A-ARs 3.1  107  1.2  107 58.6  8.7
EC50: the concentration of noradrenaline alone or in the presence of ARC 239 which elicits half the maximum contracting effect of noradrenaline. Emax: maximum
contracting effect of noradrenaline alone or in the presence of ARC 239.
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The a2-ARs, classified into three subtypes (a2A-, a2B- and
a2C-ARs), can be found at both presynaptic and postsynaptic
sites of the adrenergic synapses (Philipp et al., 2002). The
differences in the receptor subtypes and their various
localizations are thought to be responsible for their different
roles in, for example, the control of blood pressure (Link et al.,Fig. 8. Effect of the subtype-selective a2B/C-adrenoceptor antagonist ARC 239
on the noradrenaline-evoked contractions (control) in the labour-induced rat
myometrium in an isolated organ bath (n = 8). Premature labour was induced by
treatment with mifepristone s.c. 3 mg/animal) and prostaglandin E2 (0.5 mg/
animal) intravaginally on pregnancy day 19. The foetuses were usually deliv-
ered on the morning of day 20. Animals were sacrificed within 1 h before the
anticipated birth. The studies were carried out in the presence of the b-
adrenoceptor antagonist propranolol (105 M) and the a1-adrenoceptor antago-
nist doxazosin (107 M). The change in contraction was calculated via the area
under the curves and expressed in %  S.E.M. The statistical analyses were
carried out with the two-tailed unpaired t-test. *p < 0.05. ARC 239 at 107 M
significantly decreased the maximum contracting effect of noradrenaline. For
EC50 and Emax values, see Table 2.1996; Altman et al., 1999) and behaviour (Sallinen et al., 1999;
Schramm et al., 2001). Little is known, however, of the roles of
these receptor subtypes in the contractility of the uterine
smooth muscle. Earlier, the localizations of the subtypes were
studied in the late-pregnant rat myometrium, where they were
found on the surface of the myometrial cells, while they were
localized on both sides of the adrenergic synapses in the non-
pregnant myometrium (Kyozuka et al., 1988; Legrand et al.,
1993).
We identified all three a2-AR subtypes in both the non-
pregnant and the 22-day-pregnant rat uteri. An earlier study did
not detect a2C-AR in the rat myometrium, though in that work
(Bouet-Alard et al., 1997) a radioligand-binding technique was
used, which has a lower specificity as compared with our RT-
PCR and Western blotting techniques, using a2-AR subtype-
specific primers and polyclonal antibodies, respectively.
The roles of a2-AR subtypes in myometrial contractility
were investigated via the effects of subtype-selective antago-
nists on the noradrenaline-stimulated contractions. Noradrena-
line was ineffective on the non-pregnant uteri, whereas KCl
enhanced the contractions. These results suggest no coupling
between the a2-ARs and adenylyl cyclase, which was
supported by cAMP studies, where the presence of the
antagonist did not alter the tissue cAMP production. This
finding reaffirmed the earlier report on the lack of connection
between a2-ARs and contractions in the non-pregnant rat
myometrium (Kyozuka et al., 1988).
Noradrenaline elicited contractions in the late-pregnant
uteri, which were mediated via the a2-ARs because of the
presence of a1- and b-AR blockers (doxazosin and proprano-
lol). Although the antagonists for the a2-AR subtypes are not
very selective, we used three compounds with acceptable
selectivity for one or two subtypes. BRL 44408, ARC 239 and
spiroxatrine were earlier found to be selective for a2A-AR, a2B/
C-AR and a2C-AR, respectively (Uhlen et al., 1992, 1997;
Renouard et al., 1994). Each of these compounds displays
various affinities for the 5-HT1A receptors (Barrett et al., 1989;
R. Ga´spa´r et al. / Neurochemistry International 51 (2007) 311–318 317Meana et al., 1996) and spiroxatrine also exerts effects in the
dopaminergic system (Costall and Naylor, 1978), but these
effects are likely to have only a low impact on the uterine
contractions stimulated by noradrenaline.
The three subtype-selective compounds offered a possibility
to investigate the results of the stimulation of only one or two
a2-AR subtypes in the contractions and in the changes in tissue
cAMP level, which are crucial in the control of the smooth
muscle contraction and relaxation (Pierce et al., 2002). In the
cAMP studies, the phosphodiesterase inhibitor IBMX was used
to block the degradation of the generated intracellular cAMP
(Schlageter et al., 1980), while forskolin was added to enhance
the activity of adenylyl cyclase (Seamon and Daly, 1986). BRL
44408 blocked the a2A-ARs, and hence noradrenaline could
stimulate only the a2B- and a2C-ARs. The simultaneous
stimulation of these two receptors mildly increased the
contractions and decreased the intracellular cAMP level. In
the presence of ARC 239, only the a2A-ARs remained free; the
stimulation of this subtype decreased the effect of noradrena-
line, with a rise in the myometrial cAMP level. Spiroxatrine
blocked the a2C-ARs, and thus the a2A- and a2B-ARs were
stimulated by the agonist, and an increase in contraction and a
decrease in the cAMP level were found. The combination BRL
44408 + spiroxatrine blocked the a2A- and a2C-ARs; the
stimulation of the free a2B-ARs also increased the uterine
contractions and decreased the amount of tissue cAMP. The
presence of the antagonists did not alter the EC50 values of the
contracting dose–response curves of noradrenaline, indicating
that the compound had the same affinity for each of the a2-ARs.
These results suggest that in the late-pregnant myometrium
a2A-ARs mediate only weak contractions, which can be regarded
as relaxation as they are compared with the effect of
noradrenaline on all the three receptor subtypes. The a2B-ARs
are responsible for strong contractions. The a2C-ARs also seem
to decrease the contractions because the contracting effect
mediated through the a2B-ARs was significantly increased when
a2C-ARs were blocked by spiroxatrine. The extent of the increase
in contraction was lower on the simultaneous stimulation of the
a2B- and a2C-ARs than in the case of the a2B- and a2A-ARs,
which can be explained by the higher density of the a2C-ARs as
compared with the a2A-ARs. Although an elevation of the
intracellular cAMP level is very unusual after stimulation of an
a2-AR, pregnancy seems to turn the G-protein activation into the
opposite direction, as we found in theb-adrenergic system in 22-
day-pregnant rats (Ga´spa´r et al., 2005). On the other hand, it has
been proved that pregnancy is able to induce a change in the Gi/
Gs-activating property ofa2-AR in rats, resulting in a differential
regulation of myometrial adenylyl cyclase activity at mid-
pregnancy versus term (Mhaouty et al., 1995). The different
functions of the postsynaptic a2-AR subtypes inside the same
tissue seem to be unique in the pregnant uterus. Although there
are some other tissues in which stimulation of the a2-AR
subtypes results in opposite effects, e.g. in the vasculature, the
stimulation of a2A-ARs and a2C-ARs causes relaxation and
contraction, respectively, but in this case the a2A-ARs are
localized presynaptically, while the a2B-ARs are located on the
postsynaptic surface (Philipp et al., 2002).Another question is why the effect of BRL 44408 + spir-
oxatrine did not exceed the contraction-increasing effect of
spiroxatrine alone. Although an increasing tendency in the
maximal contractions and a very slight decrease in the tissue
cAMP level were observed when the combination was used,
these changes were not significant as compared with the effect
of spiroxatrine. It is known that the a2-ARs are also prone to be
involved in the processes of homo- and heterodimerization. It
has additionally been proved that, when both a2A- and a2C-ARs
are expressed, there is a greater likelihood that the two
receptors will form heterodimers than homodimers. The a2C-
ARs alter a2A-AR signalling by forming oligomers (Hein,
2006; Small et al., 2006). This means that these two receptor
subtypes probably function together, although the details of
their cooperation are not well known. If the a2C-AR is also able
to alter the function of the a2A-ARs in the uterine smooth
muscle, this cooperation might give a partial explanation for the
similar maximum effects and changes in tissue cAMP levels.
Thus, if a2C-AR is blocked, the function of a2A-AR might be
modified independently from its blockade.
The uterus-contracting effect of noradrenaline can be
explained as a resultant effect mediated by the AR subtypes.
Because of the a2B-AR predominance at the end of pregnancy,
the contraction is the main resultant effect, which is altered by
the other two subtypes, mediating a decrease in the intensity of
noradrenaline-induced contractions.
ARC 239 had a marked relaxing effect on the noradrenaline-
stimulated uterine contractions; it was therefore tested on the
myometrium from the induced labour model. This test was
designed to investigate the effects of this compound on
overstimulated uterine tissue which is very close to delivery
(within 1 h). Its effect on the noradrenaline-evoked contractions
was also convincing; it can be promising in the therapy of
premature labour. The increased sensitivity of labour-induced
uteri to noradrenaline (where the EC50 value was 10 times lower
than in normal pregnancy) may mean a further advantage for
a2-AR blockers in the inhibition of premature contractions.
We can conclude that the a2-AR subtypes play different
roles in the contractility of the rat uterus. In non-pregnant
animals, they are not involved in the control of myometrial
contractions. In last-day-pregnant animals, the a2B-ARs
predominate and mediate contraction, while the a2A- and
a2C-ARs decrease the contractile response to noradrenaline.
Theoretically, if these regularities hold in human too,
stimulation of the a2A- and a2C-ARs and inhibition of the
a2B-ARs open up new targets for drugs against premature
contractions in pregnancy.
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